These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19348029)

  • 1. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
    Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
    Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
    Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
    BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
    Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
    Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
    Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
    Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Satisfaction with Flexible-dose Fesoterodine in Patients with Overactive Bladder who were Dissatisfied with Previous Anticholinergic Therapy: A Multicenter Single-Arm Clinical Study.
    Choi JB; Cho KJ; Park WH; Lee DH; Kim YH; Cho IR; Yoon H; Kim YS; Kim JC
    Urol J; 2020 Jan; 17(1):97-101. PubMed ID: 30882160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.
    Cardozo L; Hall T; Ryan J; Ebel Bitoun C; Kausar I; Darekar A; Wagg A
    Int Urogynecol J; 2012 Nov; 23(11):1581-90. PubMed ID: 22576329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.